CIMA DEVELOPING FAST-DISSOLVING ZANTAC USING ORASOLV SYSTEM
This article was originally published in The Tan Sheet
Executive Summary
CIMA DEVELOPING FAST-DISSOLVING ZANTAC USING ORASOLV SYSTEM under a license and development agreement between the Minneapolis-based R&D start-up and Glaxo. In a June 13 prospectus covering an initial public stock offering, Cima Labs reported the Glaxo agreement "to produce an OraSolv version of Zantac (ranitidine) to be marketed exclusively by Glaxo both in the U.S. and internationally."